Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0037315 (
sleep apnea
)
8,000
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Six young male patients with grade I (mild) myotonic dystrophy and a complaint of excessive daytime sleepiness were studied during wakefulness and sleep. Pulmonary function tests during wakefulness showed evidence of mild abnormality related to respiratory muscle weakness. During sleep, some patients developed a
sleep apnea syndrome
with high sleep Apnea Indices. There was no relation between hypoxic and hypercapnic ventilatory responses during wakefulness and sleep Apnea Indices. But hypoxemia and hypercapnia worsened considerably during REM sleep. Myotonic dystrophy patients with
sleep apnea
presented increased pulmonary and systemic arterial pressures during sleep. It was also during sleep that arrhythmias were observed.
Sleep 1978
Sep
PMID:Respiratory and hemodynamic study during wakefulness and sleep in myotonic dystrophy. 22 21
Fourteen patients with an average of more than 60 episodes of upper airway obstruction during night sleep were treated with a nonsedating tricyclic antidepressant, protriptyline. Frequency and duration of recorded apneas decreased in 11 cases, and satisfactory control of
sleep apnea
was maintained with medical therapy alone in 8 of these 11 patients for 7 to 15 months. Potential adverse effects of protriptyline, particularly on the cardiovascular system, limit its use in this illness. These results indicate the possibility of pharmacologic reversal of sleep-induced incoordination of the upper airway.
Neurology 1979
Sep
PMID:Sleep apnea: treatment with protriptyline. 57 9
An obese man, with an attack of myocardial ischaemia, developed arrhythmias only when he was asleep. Episodes of sinus bradycardia occurred progressing to arterioventricular block and sinus arrest. These changes in the cardiac rhythm coincided with periods of
sleep apnoea
.
Br Heart J 1978
Sep
PMID:Cardiac and respiratory standstill during sleep. 70 32
Recent awareness of the magnitude of sudden unexplained deaths in apparently healthy infants has lead to an increased interest in those circumstances that are associated with or can elicit prolonged and serious apneic episodes. In the present studies, attention was directed toward the study of physiologic activity during sleep and feeding. Apneic episodes of varying durations occur during sleep which, in some instances, can be of sufficient length to warrant resuscitative intervention. A number of infants also reveal transient upper airway obstruction following brief periods of
sleep apnea
. This functional airway obstruction produces sudden and severe bradycardia. Similarly, infant feeding can induce dangerously prolonged periods of apnea and, in some infants, transient airway obstruction. Few detailed studies have been performed to identify the anatomical level or characteristics of the obstruction. Available evidence suggests that this can take the form either of muscle hypotonicity or hypertonicity. Two infants observed by means of direct laryngoscopy revealed transient failure of vocal cord abduction. These results have provided for the development of two theoretical models that can result in the sudden infant death syndrome; furthermore, continuous recordings of respiratory and cardiac activity during feeding and sleep can be extremely valuable in elucidating the mechanisms responsible for the sudden development of apneic and cyanotic episodes in infants.
Laryngoscope 1976
Sep
PMID:Apnea and airway obstruction during feeding and sleep. 95 47
To evaluate the incidence of
sleep apnea syndrome
(
SAS
), oxygen desaturation during sleep and sleep quality in patients with chronic obstructive pulmonary disease (COPD), 30 COPD patients and 20 healthy snorers (without
SAS
) were studied. Each subject received a pulmonary function test (PFT) (simple spirometry), arterial blood gas determination and an overnight sleep study. COPD patients were divided into two groups: those with
SAS
(group I) and those without (group II). Group II patients were further subdivided into: group IIa [delta SaO2 < 15% (delta SaO2 = baseline SaO2-lowest SaO2) and group IIb (delta SaO2 > or = 15%); group IIc (baseline SaO2 > 90%) and group IId (baseline SaO2 < or = 90%). Our results showed that only six of 30 (20%) COPD patients had an associated
SAS
. Among group II patients, the lowest SaO2 and delta SaO2 were correlated with baseline SaO2, PaO2 and PaCO2 but were not correlated with age, % of ideal body weight, FVC, FEVl, FEVl/FVC. Group IIb patients (n = 10) had a lower SaO2 during sleep, a lower baseline PaO2, and a lower hematocrit level than group IIa patients (n = 14). Group IId patients (n = 9) had a lower PaO2 and a higher delta SaO2 during sleep than group IIc patients (n = 15). However, there were no significant differences in age, percent of ideal body weight (IBW), FVC, FEVl or FEVl/FVC values between groups IIa and IIb, or between groups IIc and IId. Group II patients had a lower percentage of sleep efficiency, higher arousal and movement indices and a longer period of stage 1 sleep, compared to the control group. In conclusion, the incidence of COPD patients with
SAS
is 20%. Age, percentage of IBW, FEVl, and FEVl/FVC values are not reliable predictors of the risk of nocturnal hypoxemia among COPD patients. However, a possible correlation between baseline SaO2, PaO2 and PaCO2 values and the incidence of nocturnal hypoxemia exists. Finally, COPD patients experienced a poorer quality of sleep in comparison with the control group.
J Formos Med Assoc 1992
Sep
PMID:[Sleep quality and nocturnal hypoxemia in patients with chronic obstructive pulmonary disease]. 136 10
The cerebrospinal fluid (CSF) concentrations of thyrotropin-releasing hormone (TRH), substance P (SP), 5-hydroxyindoleacetic acid (5-HIAA), homovanillic acid (HVA), and 3-methoxy-4-hydroxyphenyl glycol (MHPG) were measured in 15 consecutive patients with the
sleep apnea syndrome
(
SAS
) and in healthy control subjects. Second measurements were performed 6 months after surgical treatment in 10 of the patients. The mean (+/- SD) concentration of TRH-like immunoreactive material (TRH-LIM) (pg/ml) did not differ significantly between patients with
SAS
(8.1 +/- 2.8) and control subjects (7.5 +/- 2.2). However, postoperatively, this concentration was increased in the six clinically cured patients with
SAS
, from 6.9 +/- 2.7 to 9.4 +/- 1.6 (p less than 0.03). Substance P-like immunoreactive material (SP-LIM) was higher in untreated patients with
SAS
than in control subjects: 19.2 +/- 6.7 versus 14.4 +/- 4.2 fmol/ml (p less than 0.02), and the level remained high after operation in the group treated surgically. The HVA, 5-HIAA, and MHPG concentrations were similar in patients with
SAS
and control subjects, and no consistent changes were found postoperatively. The CSF deviations in TRH-LIM and SP-LIM concentrations in the patients may reflect a primary central nervous system defect or they may be secondary to intermittent nocturnal hypoxia, progressive hypercapnia, and/or sleep fragmentation. In this sense, both these systems may be markers of
SAS
-SP as a "trait" marker and TRH as an indicator of the current state.
Am Rev Respir Dis 1992
Sep
PMID:Substance P, thyrotropin-releasing hormone, and monoamine metabolites in cerebrospinal fluid in sleep apnea patients. 138 67
We examined the effects of high-frequency (30-Hz) low-pressure oscillations on respiration in nine patients with central
sleep apnea
. All patients were studied during sleep and wore a nasal mask through which the oscillations were applied. All tests were performed during periods of repetitive central apneas. Respiratory efforts were monitored from the airflow and calibrated Respitrace signals. After several cycles of apnea were monitored, the oscillatory pressures were applied for brief periods (less than 5 s) at the midpoint of the central apneas. All trials in which arousal occurred were discarded, leaving a total of 106 trials in the nine patients. High-frequency oscillation of the upper airway stimulated respiratory effort(s) in 68% of all trials (72 of 106). Apnea length was significantly shortened in four of the nine patients. In one patient with a tracheostomy, the stimulus applied to his isolated upper airway evoked respiratory efforts during central apnea in 13 of 15 trials. We conclude that high-frequency oscillatory pressures applied to the upper airway can stimulate respiratory efforts during central apnea. This response may be mediated by upper airway receptors involved in nonrespiratory airway defense reflexes and may have implications in the treatment of patients with central
sleep apnea
.
J Appl Physiol (1985) 1992
Sep
PMID:Effects of high-frequency pressure waves applied to upper airway on respiration in central apnea. 140 28
Breathing is a complex act requiring the coordinated activity of multiple groups of muscles. Thoracic and abdominal respiratory muscles expand and contract the lungs, whereas pharyngeal and laryngeal respiratory muscles maintain upper airway patency and regulate upper airway resistance. An appreciation of the importance of the latter muscle group in maintaining ventilatory homeostasis and in the pathophysiology of
sleep apnea
has led to extensive studies examining the neural regulation of pharyngeal dilator muscles. The present review examines the role of heterogeneity in motoneuron and muscle properties in determining the diversity in the electrical and mechanical behaviors of thoracic compared with pharyngeal muscle groups. Specifically, phrenic and hypoglossal motoneuron electrophysiological properties influence whether and the extent to which these neurons will fire in response to a given synaptic input arising from chemo- and mechanoreceptors and from respiratory and nonrespiratory pattern generators. Furthermore, thoracic and pharyngeal muscle properties determine the mechanical response to motoneuronal activity, including the speed of contraction, relationships between motoneuron firing frequency and force production, and whether force is maintained during repetitive activation. Heterogeneity in the functional capabilities of these motoneurons and muscles is in turn determined by diversity of their structural and biochemical properties. Thus, intrinsic properties of respiratory motoneurons and muscles act in concert with neuronal drives in defining the complex electrical and mechanical behavior of pharyngeal and thoracic respiratory motor systems.
J Appl Physiol (1985) 1992
Sep
PMID:Intrinsic properties of pharyngeal and diaphragmatic respiratory motoneurons and muscles. 140 39
It is well documented that upper airway (UAW) muscle activity is augmented in response to increased respiratory drive, the overall effect being an improvement in UAW patency. We have recently shown that salicylate-induced ventilatory stimulation increased UAW muscle electrical activity and decreased UAW resistance and collapsibility in anesthetized dogs. In the present study, we evaluated the effect of respiratory stimulation produced by high therapeutic doses of aspirin on sleep in nine patients with previously diagnosed
sleep apnea
. A control, all-night, polysomnographic sleep study, including oximetry and ventilatory monitoring by inductive plethysmography, was compared with a second study undertaken after patients ingested 8 to 10 g of aspirin over a period of 4 to 5 h. Aspirin ingestion resulted in high therapeutic salicylate serum levels (33 +/- 2.5 mg/dl, mean +/- SE) the following morning and was associated with marked ventilatory stimulation. Mean sleep duration and the relative partitioning of sleep stages were not affected by aspirin. However, aspirin-induced hyperventilation was associated with a significant non-rapid decrease in periodic breathing and the frequency of both obstructive and mixed apneas in all non-rapid eye movement (REM) sleep stages. The total number of apneas over the whole night was reduced in all subjects and on average fell from a control rate of 42 +/- 7 to 28 +/- 7 apneas/h (p less than 0.01). Similarly, the mean duration of apneas fell from 23 +/- 2 to 20 +/- 1 s (p less than 0.05), and the overall time spent in apneas decreased from 17 +/- 3 to 10 +/- 3 min/h (p less than 0.01).(ABSTRACT TRUNCATED AT 250 WORDS)
Am Rev Respir Dis 1992
Sep
PMID:Amelioration of sleep apnea by salicylate-induced hyperventilation. 151 52
Research efforts to date have determined that both anatomic and physiologic variables may contribute to the pathophysiology of OSA. Whether specific factors within either of these two categories will be shown to predominate remains to be seen. Surely, experience with
sleep apnea
patients teaches us that different variables are important in different OSA patients. However, even those patients who initially appear to have predominantly an anatomic or physiologic cause of their OSA often fail to respond to specific treatment. Treatment failure implies the following: (1) The initial impression of the importance of a given variable was wrong. This may happen in the patient who has a narrow transpalatal airway and fails to respond to uvulopalatopharyngoplasty. In this individual, physiologic variables such as pharyngeal collapsibility or periodic breathing may need to be addressed. Of course, the reverse may occur; patients may be treated pharmacologically for an assumed physiologic mechanism and important anatomic factors may have been overlooked. Our ability to differentiate the importance of these different variables is poor. Therefore, our diagnostic acumen needs further refinement. (2) Of course, it is likely that the proper diagnosis was made, but the therapy chosen was imperfect. In the area of anatomy, investigators are just beginning to try surgical approaches designed specifically for the pharyngeal site of obstruction. In other words, uvulopalatopharyngoplasty is not the best approach for everyone. In physiology, treatments beyond continuous positive airway pressure will be needed. It is hoped that advances in the pharmacology of sleep disorders will establish more convenient and successful therapies. It is likely that OSA is a heterogenous disease process. We must realize that a treatment that helps one patient may not be applicable to the next individual. Through a better understanding of the pathophysiology of OSA, better treatment modalities should be developed, resulting in improved quality of life for OSA patients.
Clin Chest Med 1992
Sep
PMID:The role of upper airway anatomy and physiology in obstructive sleep apnea. 152 8
1
2
3
4
5
6
7
8
9
10
Next >>